Pioneering genetic-testing company Myriad's biggest new product is facing pushback from US regulators that could 'significantly limit' the test's appeal. The stock is down 40%.

This is a Business Insider Prime story. Click the link below to read it.

Read Full story

Add Comment()
Comments ()
Sort By:
Be the first one to comment.
We have sent you a verification email. This comment will be published once verification is done.